<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03281772</url>
  </required_header>
  <id_info>
    <org_study_id>AAMTI 6422</org_study_id>
    <nct_id>NCT03281772</nct_id>
  </id_info>
  <brief_title>Uncontrolled Hypertension Management (TEAM-HTN)</brief_title>
  <acronym>TEAM-HTN</acronym>
  <official_title>Technology Assisted Management of Uncontrolled Hypertension (TEAM-HTN): a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Madigan Army Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Telemedicine &amp; Advanced Technology Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Analytics4Medicine, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Madigan Army Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current guideline directed medical therapies (GDMT) for hypertension (HTN) endorse a trial&#xD;
      and error approach based on drug class. This pilot study will evaluate the efficacy of a&#xD;
      Clinical Decision Support (CDS) program to assist providers with delivering a more&#xD;
      personalized approach using individual renin-aldosterone levels and the mechanism of action&#xD;
      of medications included in GDMT recommendations. The overarching goal is to achieve HTN&#xD;
      control rates above the 2014 National Health and Nutrition Examination Survey reported rate&#xD;
      of 53% in a timely fashion, by individualizing medication management, thereby reducing the&#xD;
      patient risk of stroke, heart and renal disease, and other devastating HTN-related outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current guideline directed medical therapies (GDMT) for hypertension (HTN) endorse a trial&#xD;
      and error approach based on drug class. This pilot study will evaluate the efficacy of a&#xD;
      Clinical Decision Support (CDS) program to assist providers with delivering a more&#xD;
      personalized approach using individual renin-aldosterone levels and the mechanism of action&#xD;
      of medications included in GDMT recommendations. Current research suggests underlying&#xD;
      mechanisms of HTN can be categorized by renin and aldosterone levels into approximately 50&#xD;
      categories and sub-categories. Timely identification of a patients' category is challenging&#xD;
      for clinicians and possibly a contributing factor to the low rates of HTN control reported in&#xD;
      the 2014 National Health and Nutrition Examination Survey (NHANES) of 53%. The overarching&#xD;
      goal of this study is to achieve HTN control rates above the 2014 NANES rate in a timely,&#xD;
      cost-effective manner by individualizing medication management, thereby reducing the patient&#xD;
      risk of stroke, heart and renal disease, and other devastating HTN-related outcomes. Specific&#xD;
      aims are: 1) evaluate the efficacy of the CDS software program to assist providers in&#xD;
      identifying and matching the underlying mechanisms of HTN with the mechanism of action of&#xD;
      antihypertensive medications to achieve better HTN control rates than the 53% reported in the&#xD;
      2014 NHANES data, 2) assess the efficacy of the CDS program across prescribing provider&#xD;
      levels (MD/DO, residents, and APRN/PA), and 3) Determine the impact of the CDS program on: a)&#xD;
      medication costs, b) provider management time, c), provider and patient satisfaction with and&#xD;
      perception of usability and efficacy of the CDS program to manage their blood pressure. This&#xD;
      2-phase, prospective, within-subjects, repeated measures pilot study will enroll up to 20&#xD;
      multi-level providers with prescriptive authority and 160 military beneficiaries with&#xD;
      uncontrolled HTN in the Northwest to evaluate the efficacy, feasibility, and usability of a&#xD;
      CDS program to improve blood pressure control over a six-month period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 24, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patients with controlled hypertension</measure>
    <time_frame>6 months</time_frame>
    <description>Percent of systolic and diastolic blood pressure readings within patient-specific target goals averaged in 10-day cycles at least 70% of the time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Provider Satisfaction</measure>
    <time_frame>6 months</time_frame>
    <description>Provider satisfaction with efficacy, feasibility and usability of the clinical decision software program</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>6 months</time_frame>
    <description>Patient satisfaction with efficacy, feasibility and usability of the clinical decision software program</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Provider time</measure>
    <time_frame>6 months</time_frame>
    <description>Time in minutes each provider spends per patient managing uncontrolled hypertension.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication costs</measure>
    <time_frame>6 months</time_frame>
    <description>Costs of medications per patient to achieve controlled hypertension using a published relative value scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach blood pressure goals</measure>
    <time_frame>6 months</time_frame>
    <description>Number of days from enrollment patients are not at target (70% control rate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with controlled hypertension by provider</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients per provider level (MD, DO, Nurse Practitioner, Physician Assistant) with controlled hypertension</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Uncontrolled Hypertension</condition>
  <arm_group>
    <arm_group_label>Provider</arm_group_label>
    <description>Consented providers with prescriptive privileges will use the clinical decision software - provider portal to manage study patients with uncontrolled hypertension for 6 months. Participants will conduct a baseline face-to-face visit with study patients, access the program daily to check for patient high blood pressure alerts and lab results, conduct virtual visits as needed every 7 - 10 days, track the time and number of patients managed using the program and complete two questionnaires.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>In a 6 month period, participants with uncontrolled hypertension will attend an initial face-to-face visit with a study provider, monitor their blood pressures 3x/week at home, enter their blood pressure readings manually or digitally into the clinical decision software - patient portal, get up to 4 blood draws, participate into up to 3 virtual visits monthly, and complete a questionnaire.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical Decision Software - provider portal</intervention_name>
    <description>As noted in Arms</description>
    <arm_group_label>Provider</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical Decision Software - patient portal</intervention_name>
    <description>As noted in Arms</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Credentialed providers with prescriptive authority and patients with uncontrolled&#xD;
        hypertension practicing at or enrolled in a military treatment facility in the Pacific&#xD;
        Northwest.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Providers with prescriptive authority practicing in outpatient clinics at a military&#xD;
             treatment facility in the Northwest.&#xD;
&#xD;
          2. Patients 18 years or older with uncontrolled hypertension receiving care in an&#xD;
             outpatient setting that can give a valid consent (over age 18 years, the ability to&#xD;
             read and understand English, and cognitively intact). Active duty service members who&#xD;
             will not be deployed or due to change duty station for the duration of the study.&#xD;
&#xD;
             -&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
        1. Credentialed providers without prescribing privileges in good standing. 2. Age less than&#xD;
        18 years, night shift workers, anyone who cannot give a valid informed consent, pregnant or&#xD;
        breast feeding women, prisoners, patients on renal dialysis, transplant recipients, life&#xD;
        expectancy less than 1 year, and those disqualified during screening procedures.&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leilani A. Siaki, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Madigan Army Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leilani A Siaki, PhD</last_name>
    <phone>253-698-2289</phone>
    <email>leilani.a.siaki.mil@mail.mil</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Victor S Lin, MD</last_name>
    <phone>253-968-1885</phone>
    <email>victor.s.lin.mil@mail.mil</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Madigan Army Medical Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98431-1100</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5;311(5):507-20. doi: 10.1001/jama.2013.284427. Erratum In: JAMA. 2014 May 7;311(17):1809.</citation>
    <PMID>24352797</PMID>
  </reference>
  <reference>
    <citation>Kisaka T, Ozono R, Ishida T, Higashi Y, Oshima T, Kihara Y. Association of elevated plasma aldosterone-to-renin ratio with future cardiovascular events in patients with essential hypertension. J Hypertens. 2012 Dec;30(12):2322-30. doi: 10.1097/HJH.0b013e328359862d.</citation>
    <PMID>23107914</PMID>
  </reference>
  <reference>
    <citation>Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, Flack JM, Carter BL, Materson BJ, Ram CV, Cohen DL, Cadet JC, Jean-Charles RR, Taler S, Kountz D, Townsend R, Chalmers J, Ramirez AJ, Bakris GL, Wang J, Schutte AE, Bisognano JD, Touyz RM, Sica D, Harrap SB. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014 Jan;32(1):3-15. doi: 10.1097/HJH.0000000000000065. No abstract available.</citation>
    <PMID>24270181</PMID>
  </reference>
  <reference>
    <citation>Moran AE, Odden MC, Thanataveerat A, Tzong KY, Rasmussen PW, Guzman D, Williams L, Bibbins-Domingo K, Coxson PG, Goldman L. Cost-effectiveness of hypertension therapy according to 2014 guidelines. N Engl J Med. 2015 Jan 29;372(5):447-55. doi: 10.1056/NEJMsa1406751. Erratum In: N Engl J Med. 2015 Apr 23;372(17):1677.</citation>
    <PMID>25629742</PMID>
  </reference>
  <reference>
    <citation>SPRINT Research Group; Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015 Nov 26;373(22):2103-16. doi: 10.1056/NEJMoa1511939. Epub 2015 Nov 9. Erratum In: N Engl J Med. 2017 Dec 21;377(25):2506.</citation>
    <PMID>26551272</PMID>
  </reference>
  <reference>
    <citation>Yoon SS, Fryar CD, Carroll MD. Hypertension prevalence and control among adults: United States, 2011-2014. Data from the National Health and Nutrition Examination Survey. http://www.cdc.gov/nchs/products/databriefs/db220.htm . Accessed March 18, 2016.</citation>
  </reference>
  <reference>
    <citation>Bochud M, Burnier M, Guessous I. Top Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular Medicine. Curr Pharmacogenomics Person Med. 2011 Dec;9(4):299-322. doi: 10.2174/187569211798377135.</citation>
    <PMID>23049672</PMID>
  </reference>
  <reference>
    <citation>Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, Cannon CP, de Lemos JA, Elliott WJ, Findeiss L, Gersh BJ, Gore JM, Levy D, Long JB, O'Connor CM, O'Gara PT, Ogedegbe G, Oparil S, White WB; American Heart Association, American College of Cardiology, and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Hypertension. 2015 Jun;65(6):1372-407. doi: 10.1161/HYP.0000000000000018. Epub 2015 Mar 31. No abstract available. Erratum In: Hypertension. 2016 Oct;68(4):e61.</citation>
    <PMID>25828847</PMID>
  </reference>
  <reference>
    <citation>Deal, P. (2011). Hypertension: More Soldiers die from silent killer than combat. Army News Front Page. Retrieved October 24, 2015 from: http://www.army.mil/article/59005/</citation>
  </reference>
  <reference>
    <citation>Wang G, Fang J, Ayala C. Hypertension-associated hospitalizations and costs in the United States, 1979-2006. Blood Press. 2014 Apr;23(2):126-33. doi: 10.3109/08037051.2013.814751. Epub 2013 Jul 25.</citation>
    <PMID>23885763</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>September 11, 2017</study_first_submitted>
  <study_first_submitted_qc>September 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2017</study_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>clinical decision support software</keyword>
  <keyword>renin</keyword>
  <keyword>aldosterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03281772
org study id: AAMTI 6422
nct id: NCT03281772
lead sponsor: 
collaborator: 
collaborator: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
Current guideline directed medical therapies (GDMT) for hypertension (HTN) endorse a trial
      and error approach based on drug class. This pilot study will evaluate the efficacy of a
      Clinical Decision Support (CDS) program to assist providers with delivering a more
      personalized approach using individual renin-aldosterone levels and the mechanism of action
      of medications included in GDMT recommendations. The overarching goal is to achieve HTN
      control rates above the 2014 National Health and Nutrition Examination Survey reported rate
      of 53% in a timely fashion, by individualizing medication management, thereby reducing the
      patient risk of stroke, heart and renal disease, and other devastating HTN-related outcomes.
Current guideline directed medical therapies (GDMT) for hypertension (HTN) endorse a trial
      and error approach based on drug class. This pilot study will evaluate the efficacy of a
      Clinical Decision Support (CDS) program to assist providers with delivering a more
      personalized approach using individual renin-aldosterone levels and the mechanism of action
      of medications included in GDMT recommendations. Current research suggests underlying
      mechanisms of HTN can be categorized by renin and aldosterone levels into approximately 50
      categories and sub-categories. Timely identification of a patients' category is challenging
      for clinicians and possibly a contributing factor to the low rates of HTN control reported in
      the 2014 National Health and Nutrition Examination Survey (NHANES) of 53%. The overarching
      goal of this study is to achieve HTN control rates above the 2014 NANES rate in a timely,
      cost-effective manner by individualizing medication management, thereby reducing the patient
      risk of stroke, heart and renal disease, and other devastating HTN-related outcomes. Specific
      aims are: 1) evaluate the efficacy of the CDS software program to assist providers in
      identifying and matching the underlying mechanisms of HTN with the mechanism of action of
      antihypertensive medications to achieve better HTN control rates than the 53% reported in the
      2014 NHANES data, 2) assess the efficacy of the CDS program across prescribing provider
      levels (MD/DO, residents, and APRN/PA), and 3) Determine the impact of the CDS program on: a)
      medication costs, b) provider management time, c), provider and patient satisfaction with and
      perception of usability and efficacy of the CDS program to manage their blood pressure. This
      2-phase, prospective, within-subjects, repeated measures pilot study will enroll up to 20
      multi-level providers with prescriptive authority and 160 military beneficiaries with
      uncontrolled HTN in the Northwest to evaluate the efficacy, feasibility, and usability of a
      CDS program to improve blood pressure control over a six-month period.
observational model: Case-Only
time perspective: Prospective
measure: Patients with controlled hypertension
time frame: 6 months
description: Percent of systolic and diastolic blood pressure readings within patient-specific target goals averaged in 10-day cycles at least 70% of the time.
measure: Provider Satisfaction
time frame: 6 months
description: Provider satisfaction with efficacy, feasibility and usability of the clinical decision software program
measure: Patient Satisfaction
time frame: 6 months
description: Patient satisfaction with efficacy, feasibility and usability of the clinical decision software program
measure: Provider time
time frame: 6 months
description: Time in minutes each provider spends per patient managing uncontrolled hypertension.
measure: Medication costs
time frame: 6 months
description: Costs of medications per patient to achieve controlled hypertension using a published relative value scale
measure: Time to reach blood pressure goals
time frame: 6 months
description: Number of days from enrollment patients are not at target (70% control rate)
measure: Patients with controlled hypertension by provider
time frame: 6 months
description: Number of patients per provider level (MD, DO, Nurse Practitioner, Physician Assistant) with controlled hypertension
arm group label: Provider
description: Consented providers with prescriptive privileges will use the clinical decision software - provider portal to manage study patients with uncontrolled hypertension for 6 months. Participants will conduct a baseline face-to-face visit with study patients, access the program daily to check for patient high blood pressure alerts and lab results, conduct virtual visits as needed every 7 - 10 days, track the time and number of patients managed using the program and complete two questionnaires.
arm group label: Patients
description: In a 6 month period, participants with uncontrolled hypertension will attend an initial face-to-face visit with a study provider, monitor their blood pressures 3x/week at home, enter their blood pressure readings manually or digitally into the clinical decision software - patient portal, get up to 4 blood draws, participate into up to 3 virtual visits monthly, and complete a questionnaire.
intervention type: Other
intervention name: Clinical Decision Software - provider portal
description: As noted in Arms
arm group label: Provider
intervention type: Other
intervention name: Clinical Decision Software - patient portal
description: As noted in Arms
arm group label: Patients
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: Accepts Healthy Volunteers
last name: Leilani A. Siaki, PhD
role: Principal Investigator
affiliation: Madigan Army Medical Center
last name: Leilani A Siaki, PhD
phone: 253-698-2289
email: leilani.a.siaki.mil@mail.mil
last name: Victor S Lin, MD
phone: 253-968-1885
email: victor.s.lin.mil@mail.mil
facility: 
status: Recruiting
country: United States
citation: James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5;311(5):507-20. doi: 10.1001/jama.2013.284427. Erratum In: JAMA. 2014 May 7;311(17):1809.
PMID: 24352797
citation: Kisaka T, Ozono R, Ishida T, Higashi Y, Oshima T, Kihara Y. Association of elevated plasma aldosterone-to-renin ratio with future cardiovascular events in patients with essential hypertension. J Hypertens. 2012 Dec;30(12):2322-30. doi: 10.1097/HJH.0b013e328359862d.
PMID: 23107914
citation: Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, Flack JM, Carter BL, Materson BJ, Ram CV, Cohen DL, Cadet JC, Jean-Charles RR, Taler S, Kountz D, Townsend R, Chalmers J, Ramirez AJ, Bakris GL, Wang J, Schutte AE, Bisognano JD, Touyz RM, Sica D, Harrap SB. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014 Jan;32(1):3-15. doi: 10.1097/HJH.0000000000000065. No abstract available.
PMID: 24270181
citation: Moran AE, Odden MC, Thanataveerat A, Tzong KY, Rasmussen PW, Guzman D, Williams L, Bibbins-Domingo K, Coxson PG, Goldman L. Cost-effectiveness of hypertension therapy according to 2014 guidelines. N Engl J Med. 2015 Jan 29;372(5):447-55. doi: 10.1056/NEJMsa1406751. Erratum In: N Engl J Med. 2015 Apr 23;372(17):1677.
PMID: 25629742
citation: SPRINT Research Group; Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015 Nov 26;373(22):2103-16. doi: 10.1056/NEJMoa1511939. Epub 2015 Nov 9. Erratum In: N Engl J Med. 2017 Dec 21;377(25):2506.
PMID: 26551272
citation: Yoon SS, Fryar CD, Carroll MD. Hypertension prevalence and control among adults: United States, 2011-2014. Data from the National Health and Nutrition Examination Survey. http://www.cdc.gov/nchs/products/databriefs/db220.htm . Accessed March 18, 2016.
citation: Bochud M, Burnier M, Guessous I. Top Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular Medicine. Curr Pharmacogenomics Person Med. 2011 Dec;9(4):299-322. doi: 10.2174/187569211798377135.
PMID: 23049672
citation: Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, Cannon CP, de Lemos JA, Elliott WJ, Findeiss L, Gersh BJ, Gore JM, Levy D, Long JB, O'Connor CM, O'Gara PT, Ogedegbe G, Oparil S, White WB; American Heart Association, American College of Cardiology, and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Hypertension. 2015 Jun;65(6):1372-407. doi: 10.1161/HYP.0000000000000018. Epub 2015 Mar 31. No abstract available. Erratum In: Hypertension. 2016 Oct;68(4):e61.
PMID: 25828847
citation: Deal, P. (2011). Hypertension: More Soldiers die from silent killer than combat. Army News Front Page. Retrieved October 24, 2015 from: http://www.army.mil/article/59005/
citation: Wang G, Fang J, Ayala C. Hypertension-associated hospitalizations and costs in the United States, 1979-2006. Blood Press. 2014 Apr;23(2):126-33. doi: 10.3109/08037051.2013.814751. Epub 2013 Jul 25.
PMID: 23885763
responsible party type: Sponsor
mesh term: Hypertension
sharing ipd: No